At present, there are no disease-modifying treatments to stall the progression of Parkinson’s disease (PD). A drug in development to treat diabetes might provide a way to slow it down. The drug, MSDC-0160, targets a recently identified carrier of pyruvate (a major substrate for energy production) into mitochondria . Ghosh et al. successfully used the drug to block neurodegeneration in several different cellular and animal models of PD. Furthermore, in two mouse models of PD, cellular autophagy was restored and neuroinflammation was reduced.focuz.ru
